Movers of the Week: Who Led and Who Fell (Week Ending 30 Oct 2026)

As of 30 Oct 2026 close. Weekly change measured from the 23 Oct 2026 close to the 30 Oct 2026 close.

Each week we list the biggest weekly moves among US-listed stocks, whatever the company does. Stocks under $2 and thinly traded stocks are left out. Each name carries a short label from our ethical screen and boycott check, so you can see where it stands and decide for yourself. The “why” lines are plain-words context, not predictions.

Show only stocks that pass our ethical screen

What do these labels mean?

Biggest gainers

1. SGRY Surgery Partners, +47.4% ($15.75 to $23.21). Jumped about 48% on 26 Oct after a report that Bon Secours Mercy Health was in advanced talks to buy a majority stake. No deal had been announced.
   Does not pass our screen: debt above our limit
2. FTFT Future FinTech Group, +46.0% ($2.00 to $2.92). No clear news reason found. Most of the gain came on 28 Oct.
   Passes our ethical screen
3. GIBO GIBO Holdings, +45.9% ($59.65 to $87.02). No clear news reason found. The gain built over the week, with the biggest day on 30 Oct.
   Does not pass our screen: debt above our limit
4. ADT ADT, +42.9% ($6.90 to $9.86). No clear news reason found. Most of the gain came on 29 Oct.
   Does not pass our screen: debt above our limit
5. NFE New Fortress Energy, +41.4% ($3.48 to $4.92). No clear news reason found. Most of the gain came on 30 Oct.
   Does not pass our screen: debt above our limit

None of this week's top five pass our screen.

Biggest decliners

1. PICS PicS N.V., -48.6% ($13.80 to $7.10). No clear news reason found. Most of the fall came on 26 and 27 Oct.
   Our screen: potentially compliant, not yet confirmed
2. BCAX Bicara Therapeutics, -46.5% ($17.07 to $9.13). No clear news reason found. Most of the fall came on 28 Oct.
   Does not pass our screen: interest-bearing holdings above our limit
3. CPIX Cumberland Pharmaceuticals, -44.8% ($8.49 to $4.69). Released top-line results from a mid-stage trial late on 23 Oct. The trial showed safety but was not designed to show the drug works, and the shares fell about 49% on 26 Oct.
   Passes our ethical screen
4. INTR Inter & Co, -44.2% ($7.19 to $4.01). No clear news reason found. Most of the fall came on 26 Oct.
   Does not pass our screen: business activity (conventional finance)
5. IOVA Iovance Biotherapeutics, -39.8% ($14.09 to $8.48). No clear news reason found. Most of the fall came on 29 Oct.
   Passes our ethical screen

None of this week's top five pass our screen.

Under review

Moves above 50% in a week are held back until the data is confirmed, and are not featured. This week: ULBI (up), MGN (up), BOOM (up), AEYE (up), PMN (down), GDYN (up), REPL (up), XP (down).

How to read this

Big weekly moves often come from earnings, deals and trial results, and small stocks swing hard on little news. A name appearing here says it moved. It says nothing about where it goes next. Each label links to that company's page, with the full ethical read: business activity, debt, income and holdings checks, with halal and Shariah-aware criteria for readers who follow them.

Ethical considerations

• PicS N.V.: passes our debt check, but its debt is about 92% of its market value, above the 30% limit in the stricter AAOIFI standard.

Our screen and boycott check are a starting point; your own ethical judgement comes first.

Not financial advice.

Data: daily closes, 23 Oct 2026 and 30 Oct 2026, checked against a second source. As of 30 Oct 2026 close.